OKYO Pharma CEO to Speak at BTIG Ophthalmology Day
Ticker: OKYO · Form: 6-K · Filed: Nov 26, 2024 · CIK: 1849296
Sentiment: neutral
Topics: investor-relations, conference, ophthalmology
TL;DR
OKYO Pharma CEO speaking at BTIG Ophthalmology Day Dec 2nd. Get ready for updates!
AI Summary
OKYO Pharma Ltd announced on November 26, 2024, that its CEO, Gary S. Jacob, Ph.D., will participate in the 4th Annual Virtual BTIG Ophthalmology Day on December 2nd, 2024. He will engage in one-on-one meetings and a fireside chat at the event, which will feature over 20 public companies.
Why It Matters
This participation offers OKYO Pharma an opportunity to present its developments and engage with investors and industry professionals, potentially increasing visibility and interest in the company.
Risk Assessment
Risk Level: low — The filing is an announcement of participation in an industry event, which carries minimal inherent risk.
Key Numbers
- 4th — Annual BTIG Ophthalmology Day (Indicates the recurring nature and maturity of the event.)
- 20+ — Public Companies (Highlights the scale of investor and industry participation.)
Key Players & Entities
- OKYO Pharma Ltd (company) — Registrant
- Gary S. Jacob, Ph.D. (person) — CEO of OKYO Pharma Ltd
- December 2nd, 2024 (date) — Date of BTIG Ophthalmology Day
- November 26, 2024 (date) — Date of announcement
FAQ
What is the specific focus of OKYO Pharma's participation at the BTIG Ophthalmology Day?
The filing states that CEO Gary S. Jacob, Ph.D., will be participating in one-on-one meetings and a fireside chat, but does not specify the exact topics to be discussed.
Will there be any material non-public information disclosed during the event?
The filing does not indicate that material non-public information will be disclosed; typically, such events are for general corporate updates and investor relations.
What is the significance of OKYO Pharma's participation in this event?
Participation allows OKYO Pharma to increase its visibility among investors and industry peers, potentially leading to new partnerships or investment opportunities.
Who is the primary audience for the BTIG Ophthalmology Day?
The event is focused on the ophthalmology sector and likely targets investors, analysts, and other stakeholders interested in companies within this field.
Where is OKYO Pharma Ltd headquartered?
OKYO Pharma Ltd is headquartered at 9th Floor, 107 Cheapside, London EC2V 6DN.
Filing Stats: 382 words · 2 min read · ~1 pages · Grade level 13 · Accepted 2024-11-26 07:00:33
Filing Documents
- form6-k.htm (6-K) — 24KB
- ex99-1.htm (EX-99.1) — 13KB
- ex99-1_001.jpg (GRAPHIC) — 16KB
- 0001493152-24-047738.txt ( ) — 59KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. OKYO Pharma LTD Date: November 26, 2024 By: /s/ Keeren Shah Name: Keeren Shah Title: Chief Financial Officer 3 EXHIBIT INDEX Exhibit No. Description 99.1 Announcement, dated November 26, 2024 4